Phase II trial of N-methylformamide in advanced head and neck cancer

Walter C. Vogel, Arlene A. Forastiere, Ronald B. Natale, Bonnie J. Takasugi, Gary Schnur

Research output: Contribution to journalArticle

Abstract

Eighteen patients with advanced epidermoid carcinoma of the head and neck were entered into a phase II trial of N-Methylformamide (NMF), 800 mg/M2 IV daily for 5 days every 4 weeks. Seventeen patients had received prior radiation therapy and 11 were previously treated with chemotherapy. No complete or partial responses were observed. The major toxicity was gastrointestinal. Fifty percent of patients experienced nausea and vomiting or reversible hepatotoxicity with greater than a 3-fold elevation of liver enzymes. Mild reversible myelosuppression occurred in 2 patients. NMF in this dose and schedule was not a useful agent to treat recurrent epidermoid carcinoma of the head and neck.

Original languageEnglish (US)
Pages (from-to)203-206
Number of pages4
JournalInvestigational New Drugs
Volume5
Issue number2
DOIs
StatePublished - Jun 1987
Externally publishedYes

Fingerprint

methylformamide
Head and Neck Neoplasms
Squamous Cell Carcinoma
Neck
Head
Nausea
Vomiting
Appointments and Schedules
Radiotherapy
Drug Therapy
Liver
Enzymes

Keywords

  • head and neck cancer
  • N-methylformamide
  • phase II trial

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Phase II trial of N-methylformamide in advanced head and neck cancer. / Vogel, Walter C.; Forastiere, Arlene A.; Natale, Ronald B.; Takasugi, Bonnie J.; Schnur, Gary.

In: Investigational New Drugs, Vol. 5, No. 2, 06.1987, p. 203-206.

Research output: Contribution to journalArticle

Vogel, Walter C. ; Forastiere, Arlene A. ; Natale, Ronald B. ; Takasugi, Bonnie J. ; Schnur, Gary. / Phase II trial of N-methylformamide in advanced head and neck cancer. In: Investigational New Drugs. 1987 ; Vol. 5, No. 2. pp. 203-206.
@article{26382ea8f96b49faadaf39d8ea19b6cc,
title = "Phase II trial of N-methylformamide in advanced head and neck cancer",
abstract = "Eighteen patients with advanced epidermoid carcinoma of the head and neck were entered into a phase II trial of N-Methylformamide (NMF), 800 mg/M2 IV daily for 5 days every 4 weeks. Seventeen patients had received prior radiation therapy and 11 were previously treated with chemotherapy. No complete or partial responses were observed. The major toxicity was gastrointestinal. Fifty percent of patients experienced nausea and vomiting or reversible hepatotoxicity with greater than a 3-fold elevation of liver enzymes. Mild reversible myelosuppression occurred in 2 patients. NMF in this dose and schedule was not a useful agent to treat recurrent epidermoid carcinoma of the head and neck.",
keywords = "head and neck cancer, N-methylformamide, phase II trial",
author = "Vogel, {Walter C.} and Forastiere, {Arlene A.} and Natale, {Ronald B.} and Takasugi, {Bonnie J.} and Gary Schnur",
year = "1987",
month = "6",
doi = "10.1007/BF00203547",
language = "English (US)",
volume = "5",
pages = "203--206",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Phase II trial of N-methylformamide in advanced head and neck cancer

AU - Vogel, Walter C.

AU - Forastiere, Arlene A.

AU - Natale, Ronald B.

AU - Takasugi, Bonnie J.

AU - Schnur, Gary

PY - 1987/6

Y1 - 1987/6

N2 - Eighteen patients with advanced epidermoid carcinoma of the head and neck were entered into a phase II trial of N-Methylformamide (NMF), 800 mg/M2 IV daily for 5 days every 4 weeks. Seventeen patients had received prior radiation therapy and 11 were previously treated with chemotherapy. No complete or partial responses were observed. The major toxicity was gastrointestinal. Fifty percent of patients experienced nausea and vomiting or reversible hepatotoxicity with greater than a 3-fold elevation of liver enzymes. Mild reversible myelosuppression occurred in 2 patients. NMF in this dose and schedule was not a useful agent to treat recurrent epidermoid carcinoma of the head and neck.

AB - Eighteen patients with advanced epidermoid carcinoma of the head and neck were entered into a phase II trial of N-Methylformamide (NMF), 800 mg/M2 IV daily for 5 days every 4 weeks. Seventeen patients had received prior radiation therapy and 11 were previously treated with chemotherapy. No complete or partial responses were observed. The major toxicity was gastrointestinal. Fifty percent of patients experienced nausea and vomiting or reversible hepatotoxicity with greater than a 3-fold elevation of liver enzymes. Mild reversible myelosuppression occurred in 2 patients. NMF in this dose and schedule was not a useful agent to treat recurrent epidermoid carcinoma of the head and neck.

KW - head and neck cancer

KW - N-methylformamide

KW - phase II trial

UR - http://www.scopus.com/inward/record.url?scp=0023081030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023081030&partnerID=8YFLogxK

U2 - 10.1007/BF00203547

DO - 10.1007/BF00203547

M3 - Article

C2 - 3654153

AN - SCOPUS:0023081030

VL - 5

SP - 203

EP - 206

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2

ER -